#Switzerland #AliveDx #MosaiQ #Eysins #AiPlex CTDplus

AliveDx Expands Diagnostic Capabilities with MosaiQ AiPlex® CTDplus

AliveDx, a leader in in-vitro diagnostics, has recently received the prestigious IVDR-CE certification for its multiplex assay, MosaiQ AiPlex® CTDplus. This innovative test is specifically designed to enhance the diagnosis and management of systemic autoimmune rheumatic diseases (SARDs), providing a much-needed solution for healthcare providers dealing with complex autoimmune conditions.

The Challenge of Diagnosing Autoimmune Diseases

Autoimmune rheumatic diseases like rheumatoid arthritis, systemic lupus erythematosus, and scleroderma present a significant global challenge. One of the reasons for this is the overlapping symptoms and the high comorbidity rates among various connective tissue diseases. As a result, patients often experience delays in diagnosis, which can exacerbate their conditions. Detecting multiple autoantibodies along with clinical findings significantly aids physicians in understanding these disorders, yet traditional testing can be cumbersome and time-consuming.

Introducing MosaiQ AiPlex CTDplus

The MosaiQ AiPlex CTDplus facilitates a syndromic approach to diagnosing autoimmune diseases. This multiplex assay allows for the simultaneous detection of a comprehensive panel of 15 markers associated with these diseases. This feature offers healthcare providers a significant time-saving advantage, requiring only a small sample of 10 μl from patients for accurate results in a single step. The test covers most recommended autoantibodies according to relevant clinical guidelines, ensuring a thorough evaluation of patients’ conditions.

In interviews, Manuel O. Méndez, the CEO of AliveDx, emphasized the importance of early and precise diagnosis in managing complex autoimmune diseases. He stated, "We are thrilled to receive our fifth Clinical IVDR-CE mark in the past 18 months, reflecting our unwavering commitment to improving patient care. Our MosaiQ AiPlex CTDplus test is pivotal in helping labs and physicians achieve timely diagnoses."

Simplified Laboratory Workflow

Beyond its diagnostic accuracy, the MosaiQ AiPlex CTDplus system streamlines laboratory workflows. The automated, multiplex microarray technology used in the MosaiQ platform enables labs to test for up to 1,275 disease markers per hour, significantly enhancing efficiency. The intuitive interface promotes ease of use, allowing personnel to expect quick and reliable results while minimizing manual errors. The integration of RFID tags in reagents and multiplex assay trays further improves operational efficiency, freeing up valuable lab resources.

AliveDx is committed to expanding its diagnostic offerings, with plans to develop multiplex solutions specifically for vasculitis and antiphospholipid syndrome in the future. Such innovations aim to address the pressing needs for enhanced diagnostic capabilities in systemic autoimmune diseases.

A Commitment to Patient Care

AliveDx has been dedicated to advancing global diagnostic standards for over 30 years. Their mission is to transform patient care through innovation and provide healthcare professionals with tools that enable faster and more accurate diagnoses. AliveDx’s portfolio, which includes the MosaiQ, Alba, and LumiQ brands, is positioned to create economic and clinical value, all while optimizing laboratory workflows for better patient outcomes.

For more details on AliveDx and its innovative diagnostic solutions, visit AliveDx.com.

In conclusion, the introduction of the MosaiQ AiPlex CTDplus assay represents a breakthrough in the field of autoimmune diagnostics. By combining speed, accuracy, and efficiency, AliveDx continues to set the standard for diagnostic innovation, ultimately leading to improved patient care and quality of life for those affected by autoimmune diseases.